Nuvectra competitors

D. Keith Grossman was named CEO and President of Nevro in March of 2019. Mr. Grossman has over 30 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, Chief Executive Officer and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, Chief Executive Officer and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Vice Chairman of Alcon, Inc., Chairman of Outset Medical, Inc. (privately held), and Board member of ViewRay, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., and a number of privately held medical device companies. Mr. Grossman received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.

Jay Kranzler has been a Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. He is currently acting as Founder and Chief Executive Officer of Perception Neuroscience, Acting Chief Medical Officer of Pastorus, Board Member of Pastorus, Avenue Pharmaceuticals, and ImmunoBrain Checkpoint, and Advisor to small and large companies in the pharma/ biotech space. After graduating from Yale University School of Medicine with MD and PhD degrees with a focus in psychopharmacology, Dr. Kranzler joined McKinsey & Company where he contributed toward founding the Firm’s pharmaceutical practice. In 1989, he became the Chief Executive Officer of Cytel Corporation, a company focused on the development of immunomodulatory drugs. He took Cytel public, and negotiated partnerships with both global and Japanese pharmaceutical companies that set new standards for deal size and structure. After Cytel, Dr. Kranzler became Chief Executive Officer of Cypress Bioscience (formerly IMRE Corporation) where he was credited for the development of Savella™ (milnacipran) for the treatment of fibromyalgia, and Karuna Pharmaceuticals, focusing on the treatment of Schizophrenia.